Search

everythinglearnresearchcommunity

for

Search:↓

A woman with systemic sclerosis developed a unique scarring hair loss combining features of systemic sclerosis and frontal fibrosing alopecia.

Folliculitis decalvans is a rare skin disease causing hair loss and requires personalized treatment.

Women with scarring alopecia are less likely to have used hormone replacement therapy or oral contraceptives compared to those with female pattern hair loss.

Topical tofacitinib is effective in promoting hair growth for non-scarring alopecia.

Both atopy and eosinophilia are linked to more severe hair loss in people with alopecia areata.

Mouse stem cells from hair follicles can improve wound healing and reduce scarring.

The botanical shampoo with Morus alba root extract is safe and effective for treating hair loss.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

A man with HIV developed skin and hair issues after starting HIV treatment, which improved with topical treatment.

Early and aggressive treatment of scarring alopecia is important to prevent further hair follicle damage.

Trichoscopy is reliable for diagnosing different types of frontal non-scarring hair loss.

A new microneedle patch helps repair spinal cord injuries by reducing scarring and promoting nerve growth.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

CCCA is a scarring hair disorder mainly affecting people of African descent, needing better awareness and treatment.

A protein called EGFR protects hair follicle stem cells, and when it's disrupted, hair follicles can be damaged, but blocking certain pathways can restore hair growth.

Doctors use their experience to choose treatments for scarring hair loss because it's hard to diagnose and treat.

Scarring alopecia affects different hair follicle stem cells than nonscarring alopecia, and the infundibular region could be a new treatment target.

The document suggests a possible link between mast cells and scarring alopecia, recommending more research for potential treatments.

Methotrexate with corticosteroids can help regrow hair in severe alopecia areata but may cause relapses and side effects.

Mice lacking the PPARγ gene in their fat cells had almost no fat tissue, severe metabolic problems, and abnormal development of other fat-related tissues.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Advanced therapies like gene, cell, and tissue engineering show promise for hair regrowth in alopecia, but their safety and effectiveness need more verification.

Burn scars heal abnormally and more research is needed to find better treatments.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

Burn scars form abnormally due to changes in wound healing, and more research is needed to improve treatments.

Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

Platelet-rich plasma treatment is not very effective for chronic severe alopecia areata.